News | January 28, 2014

Bard’s Drug Coated Balloon, Below the Knee Clinical Trial Discussed at Leipzig Interventional Course

Bard Drug Coated Balloon Below the Knee Clinical Trial Peripheral Artery Disease
January 30, 2014 — Experts presented six-month LEVANT 2 trial results for C. R. Bard Inc.’s Lutonix drug coated balloon (DCB) and provided updates on the ongoing Lutonix Below the Knee (BTK) Clinical Trial at the Leipzig Interventional Course (LINC) in Leipzig, Germany.
The symposium took place Jan. 29. 
LEVANT 2 study design — Professor Dierk Scheinert, M.D., head of the Department of Medicine, Angiology and Cardiology, Park-Krankenhaus Hospital, Leipzig, Germany
Single center experience global SFA registry — Michael Lichtenberg, M.D., Klinikum Arnsberg, Arnsberg, Germany
BTK applications and Lutonix BTK Clinical Trial — Professor Marianne Brodmann, M.D., associate professor and assistant medical director, Division of Angiology, Medical University Graz, Austria
Techniques in complex BTK cases — Francesco Liistro, M.D., San Donato Hospital, Arezzo, Italy
Pre-clinical safety data and technology review — Renu Virmani, M.D., CVPath Institute, Gaithersburg, Maryland, United States
A single center experience with Lutonix — Peter Baron von Bilderling, M.D., Gefäßpraxis im Tal, Munich, Germany
Bard announced in June 2013 enrollment of the first patient in the Lutonix BTK Clinical Trial. The global and multi-center, randomized Investigational Device Exemption (IDE) trial is ongoing and is intended to compare the safety and effectiveness of the Lutonix 014 Drug Coated PTA Dilatation Catheter to a standard angioplasty balloon for the treatment of CLI. The trial is expected to enroll several hundred patients at 55 sites worldwide.
For more information:

Related Content

Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD) | September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD) | September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init